Patents by Inventor Sheri Miraglia

Sheri Miraglia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140179901
    Abstract: Polypeptides labelled with a donor and acceptor pair of dyes selected from a dibenzorhodamine dye and a diamino-benzophenoxazine dye are peptide conjugates which are useful for intracellular and bead-based assays with fluorescence detection. Peptide conjugates with a caspase-recognition site undergo cleavage into peptide fragments which may be detected, located, and quantitated by the changes in fluorescence. Intracellular cleavage of peptide conjugates is correlated with apoptosis.
    Type: Application
    Filed: December 11, 2013
    Publication date: June 26, 2014
    Applicant: APPLIED BIOSYSTEMS, LLC
    Inventors: Xiongwei YAN, Sheri Miraglia, Pau Miau Yuan
  • Patent number: 8623995
    Abstract: Polypeptides labelled with a donor and acceptor pair of dyes selected from a dibenzorhodamine dye and a diamino-benzophenoxazine dye are peptide conjugates which are useful for intracellular and bead-based assays with fluorescence detection. Peptide conjugates with a caspase-recognition site undergo cleavage into peptide fragments which may be detected, located, and quantitated by the changes in fluorescence. Intracellular cleavage of peptide conjugates is correlated with apoptosis.
    Type: Grant
    Filed: June 14, 2010
    Date of Patent: January 7, 2014
    Assignee: Applied Biosystems, LLC
    Inventors: Xiongwei Yan, Sheri Miraglia, Pau Miau Yuan
  • Patent number: 8084033
    Abstract: Compositions comprising a cell expressing an AC133 cell surface antigen and an antibody, or antigen binding fragment thereof, that specifically binds to the antigen are provided. Expression of the antigen is highly tissue specific. It is detected on a subset of hematopoietic progenitor and stem cells derived from human bone marrow, fetal bone marrow and liver, cord blood and adult peripheral blood. The subset of cells recognized by AC133 is CD34bright and contains substantially all of the CFU-GM activity present in the CD34+ population. This highly specific distribution of AC133 makes it exceptionally useful as a reagent for isolating and characterizing human hematopoietic progenitor and stem cells. Cells selected for expression of AC133 antigen can be further purified by selection for other hematopoietic stem cell and progenitor cell markers.
    Type: Grant
    Filed: July 8, 2008
    Date of Patent: December 27, 2011
    Assignee: Amcell Corporation
    Inventors: Amy H. Yin, Sheri Miraglia, Wayne G. Godfrey, David W. Buck
  • Publication number: 20110097758
    Abstract: Polypeptides labelled with a donor and acceptor pair of dyes selected from a dibenzorhodamine dye and a diamino-benzophenoxazine dye are peptide conjugates which are useful for intracellular and bead-based assays with fluorescence detection. Peptide conjugates with a caspase-recognition site undergo cleavage into peptide fragments which may be detected, located, and quantitated by the changes in fluorescence. Intracellular cleavage of peptide conjugates is correlated with apoptosis.
    Type: Application
    Filed: June 14, 2010
    Publication date: April 28, 2011
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Xiongwei Yan, Sheri Miraglia, Pau Miau Yuan
  • Publication number: 20100273943
    Abstract: Polypeptides labelled with a donor and acceptor pair of dyes selected from a dibenzorhodamine dye and a diamino-benzophenoxazine dye are peptide conjugates which are useful for intracellular and bead-based assays with fluorescence detection. Peptide conjugates with a caspase-recognition site undergo cleavage into peptide fragments which may be detected, located, and quantitated by the changes in fluorescence. Intracellular cleavage of peptide conjugates is correlated with apoptosis.
    Type: Application
    Filed: July 6, 2010
    Publication date: October 28, 2010
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Xiongwei YAN, Sheri Miraglia, Pau Miau Yuan
  • Publication number: 20090093052
    Abstract: A hematopoietic progenitor cell antigen and reagents, notably antibodies, that specifically bind to the antigen are provided. Expression of the antigen is highly tissue specific. It is only detected on a subset of hematopoietic progenitor cells derived from human bone marrow, fetal bone marrow and liver, cord blood and adult peripheral blood. The subset of cells recognized by AC133 is CD34bright and contains substantially all of the CFU-GM activity present in the CD34+ population. This highly specific distribution of AC133 makes it exceptionally useful as a reagent for isolating and characterizing human hematopoietic progenitor and stem cells. Cells selected for expression of AC133 antigen can be further purified by selection for other hematopoietic stem cell and progenitor cell markers.
    Type: Application
    Filed: July 8, 2008
    Publication date: April 9, 2009
    Inventors: Amy H. Yin, Sheri Miraglia, David W. Buck
  • Publication number: 20070009440
    Abstract: Polypeptides labelled with a donor and acceptor pair of dyes selected from a dibenzorhodamine dye and a diamino-benzophenoxazine dye are peptide conjugates which are useful for intracellular and bead-based assays with fluorescence detection. Peptide conjugates with a caspase-recognition site undergo cleavage into peptide fragments which may be detected, located, and quantitated by the changes in fluorescence. Intracellular cleavage of peptide conjugates is correlated with apoptosis.
    Type: Application
    Filed: June 29, 2006
    Publication date: January 11, 2007
    Applicant: APPLERA CORPORATION
    Inventors: Xiongwei Yan, Sheri Miraglia, Pau Miau Yuan
  • Publication number: 20060252109
    Abstract: Polypeptides labelled with a donor and acceptor pair of dyes selected from a dibenzorhodamine dye and a diamino-benzophenoxazine dye are peptide conjugates which are useful for intracellular and bead-based assays with fluorescence detection. Peptide conjugates with a caspase-recognition site undergo cleavage into peptide fragments which may be detected, located, and quantitated by the changes in fluorescence. Intracellular cleavage of peptide conjugates is correlated with apoptosis.
    Type: Application
    Filed: December 27, 2005
    Publication date: November 9, 2006
    Applicant: Applera Corporation
    Inventors: Xiongwei Yan, Sheri Miraglia, Pau Yuan
  • Patent number: 6979530
    Abstract: Polypeptides labelled with a donor and acceptor pair of dyes selected from a dibenzorhodamine dye and a diamino-benzophenoxazine dye are peptide conjugates which are useful for intracellular and bead-based assays with fluorescence detection. Peptide conjugates with a caspase-recognition site undergo cleavage into peptide fragments which may be detected, located, and quantitated by the changes in fluorescence. Intracellular cleavage of peptide conjugates is correlated with apoptosis.
    Type: Grant
    Filed: May 21, 2001
    Date of Patent: December 27, 2005
    Assignee: Applera Corporation
    Inventors: Xiongwei Yan, Sheri Miraglia, Pau Miau Yuan
  • Publication number: 20050214861
    Abstract: A hematopoietic progenitor cell antigen and reagents, notably antibodies, that specifically bind to the antigen are provided. Expression of the antigen is highly tissue specific. It is only detected on a subset of hematopoietic progenitor cells derived from human bone marrow, fetal bone marrow and liver, cord blood and adult peripheral blood. The subset of cells recognized by AC133 is CD34bright and contains substantially all of the CFU-GM activity present in the CD34+ population. This highly specific distribution of AC133 makes it exceptionally useful as a reagent for isolating and characterizing human hematopoietic progenitor and stem cells. Cells selected for expression of AC133 antigen can be further purified by selection for other hematopoietic stem cell and progenitor cell markers.
    Type: Application
    Filed: April 19, 2004
    Publication date: September 29, 2005
    Inventors: Amy Yin, Sheri Miraglia, David Buck
  • Publication number: 20030186214
    Abstract: Polypeptides labelled with a donor and acceptor pair of dyes selected from a dibenzorhodamine dye and a diamino-benzophenoxazine dye are peptide conjugates which are useful for intracellular and bead-based assays with fluorescence detection. Peptide conjugates with a caspase-recognition site undergo cleavage into peptide fragments which may be detected, located, and quantitated by the changes in fluorescence. Intracellular cleavage of peptide conjugates is correlated with apoptosis.
    Type: Application
    Filed: May 21, 2001
    Publication date: October 2, 2003
    Inventors: Xiongwei Yan, Sheri Miraglia, Pau Miau Yuan
  • Patent number: 6455678
    Abstract: A hematopoietic progenitor cell antigen and reagents, notably antibodies, that specifically bind to the antigen are provided. Expression of the antigen is highly tissue specific. It is only detected on a subset of hematopoietic progenitor cells derived from human bone marrow, fetal bone marrow and liver, cord blood and adult peripheral blood. The subset of cells recognized by AC133 is CD34bright and contains substantially all of the CFU-GM activity present in the CD34+ population. This highly specific distribution of AC133 makes it exceptionally useful as a reagent for isolating and characterizing human hematopoietic progenitor and stem cells. Cells selected for expression of AC133 antigen can be further purified by selection for other hematopoietic stem cell and progenitor cell markers.
    Type: Grant
    Filed: April 23, 1997
    Date of Patent: September 24, 2002
    Assignee: AmCell Corporation
    Inventors: Amy H. Yin, Sheri Miraglia, Wayne G. Godfry, David W. Buck
  • Publication number: 20010051372
    Abstract: A hematopoietic progenitor cell antigen and reagents, notably antibodies, that specifically bind to the antigen are provided. Expression of the antigen is highly tissue specific. It is only detected on a subset of hematopoietic progenitor cells derived from human bone marrow, fetal bone marrow and liver, cord blood and adult peripheral blood. The subset of cells recognized by AC133 is CD34bright and contains substantially all of the CFU-GM activity present in the CD34+ population. This highly specific distribution of AC133 makes it exceptionally useful as a reagent for isolating and characterizing human hematopoietic progenitor and stem cells. Cells selected for expression of AC133 antigen can be further purified by selection for other hematopoietic stem cell and progenitor cell markers.
    Type: Application
    Filed: June 13, 2001
    Publication date: December 13, 2001
    Inventors: Amy H. Yin, Sheri Miraglia, Wayne G. Godfrey, David W. Buck
  • Patent number: 5843633
    Abstract: An hematopoietic progenitor cell antigen, and antibodies that specifically bind to the antigen are provided. Expression of the antigen is highly tissue specific. It is only detected on a subset of hematopoietic progenitor cells derived from human bone marrow, fetal bone marrow and liver, cord blood and adult peripheral blood. The subset of cells recognized by AC133 is CD34.sup.bright, and contains substantially all of the CFU-GM activity present in the CD34.sup.+ population. This highly specific distribution of AC133 makes it exceptionally useful as a reagent for isolating and characterizing human hematopoietic progenitor and stem cells. Cells selected for expression of AC133 antigen may be further purified by selection for other hematopoietic stem cell and progenitor cell markers.
    Type: Grant
    Filed: April 26, 1996
    Date of Patent: December 1, 1998
    Assignee: Amcell Corporation
    Inventors: Amy Yin, Sheri Miraglia, David W. Buck